[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Rhea-AI Filing Summary

John E. Kao, Alignment Healthcare (ALHC) Chief Executive Officer and Director, reported multiple stock sales on 09/10/2025. The Form 4 shows three non-derivative disposition entries: 253,908 shares sold at a weighted-average price of $16.2293 (per-share range $15.74–$16.735), 101,110 shares sold at a weighted-average price of $16.8555 (per-share range $16.74–$17.24), and 180,000 shares sold under a Rule 10b5-1 plan at a weighted-average price of $16.4164 (per-share range $16.03–$16.73). The first two sales were to cover tax withholding on vested restricted stock units and are described as non-discretionary; the 180,000-share sale was executed under a pre-established 10b5-1 plan adopted 03/12/2025. Following the reported transactions, the filing indicates beneficial ownership figures of 4,634,678 shares, 4,533,568 shares, and an indirect holding of 1,193,100 shares through the JEK Trust (dated February 8, 2021) for which Mr. Kao is trustee.

Positive

• Sales include transactions to cover tax withholding on vested RSUs, indicating non-discretionary activity rather than opportunistic trading
• One sale executed under a documented Rule 10b5-1 plan adopted 03/12/2025, which supports pre-arranged trading intent and trading-plan compliance

Negative

• CEO disposed of a total of 535,018 shares on 09/10/2025, which reduces his direct equity stake
• Filing shows substantial insider holdings are partly indirect via the JEK Trust, which may complicate clarity on actual immediate insider economic exposure

Insights

Corporate Governance Expert

TL;DR: Multiple planned and tax-related insider sales by the CEO; transactions appear routine and covered by a 10b5-1 plan.

The Form 4 discloses non-discretionary sales to satisfy tax withholding on vested restricted stock units and an additional sale executed under a Rule 10b5-1 trading plan adopted on 03/12/2025. These disclosures follow typical governance practices for executive equity settlements and pre-arranged trading. The filing identifies indirect holdings via the JEK Trust, which is relevant for assessing total insider exposure. No discretionary or opportunistic trades are claimed in the filing; the reporting attorney-in-fact signature is included.

Securities Analyst

TL;DR: CEO sold a combined 535,018 shares in disclosed transactions; sales described as tax-related and pursuant to a 10b5-1 plan.

Aggregate disclosed dispositions total 535,018 shares across three entries with weighted-average prices between approximately $16.23 and $16.86. Two dispositions are explicitly to cover tax withholding on RSU vesting; one is under a 10b5-1 plan adopted 03/12/2025. The filing provides per-transaction beneficial ownership figures, including an indirect trust holding of 1,193,100 shares. The report contains ranges for individual trade prices and offers to provide exact breakdowns upon request, which preserves traceability for precise trade-level analysis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE CA 92868

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2025		S		253,908(1)	D	$16.2293(2)	4,634,678	D
Common Stock	09/10/2025		S		101,110(1)	D	$16.8555(3)	4,533,568	D
Common Stock	09/10/2025		S(4)		180,000	D	$16.4164(5)	1,193,100	I	See Footnote(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This transaction does not represent a discretionary trade by the reporting person.

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $15.74 to $16.735. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.74 to $17.24. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

4. Date of Rule 10b5-1 plan adoption: 03/12/2025

5. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.03 to $16.73. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

6. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What trades did John E. Kao report on Form 4 for ALHC?

The Form 4 reports three dispositions on 09/10/2025: 253,908 shares sold at a $15.74–$16.735 range, 101,110 shares sold at a $16.74–$17.24 range, and 180,000 shares sold under a 10b5-1 plan at a $16.03–$16.73 range.

Why were some shares sold by the CEO according to the filing?

The filing states that 253,908 and 101,110 share sales were to cover tax withholding obligations related to vested restricted stock units; the 180,000 share sale was under a pre-established 10b5-1 plan.

How many shares does John E. Kao beneficially own after the reported transactions?

The Form 4 lists beneficial ownership figures of 4,634,678 shares, 4,533,568 shares, and an indirect holding of 1,193,100 shares through the JEK Trust.

When was the 10b5-1 trading plan adopted?

The filing discloses the Rule 10b5-1 plan was adopted on 03/12/2025.

Does the Form 4 provide exact per-trade prices for the sales?

No. The Form 4 provides weighted-average prices and per-share price ranges for the multiple transactions and offers to provide full trade-level price breakdowns upon request.